Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | PRCP | P42785 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410764 | 1.00 | MC4R (0.49) | MC4RSMN1; SMN2GPR119PRCPMEN1 | |
| SCHEMBL4414387 | 1.00 | MC4R (0.49) | MC4RSMN1; SMN2GPR119PRCPMEN1 | |
| SCHEMBL3803361 | 0.92 | SMN1; SMN2 (0.48) | MC4RSMN1; SMN2GPR119PRCPMEN1 | |
| SCHEMBL3799557 | 0.92 | SMN1; SMN2 (0.48) | MC4RSMN1; SMN2GPR119PRCPMEN1 | |
| SCHEMBL3798837 | 0.92 | SMN1; SMN2 (0.48) | MC4RSMN1; SMN2GPR119PRCPMEN1 | |
| SCHEMBL4408595 | 0.91 | TACR1 (0.48) | MC4RSMN1; SMN2GPR119MEN1KMT2A | |
| SCHEMBL4407576 | 0.91 | TACR1 (0.48) | MC4RSMN1; SMN2GPR119MEN1KMT2A | |
| SCHEMBL5005980 | 0.91 | TACR1 (0.48) | MC4RSMN1; SMN2GPR119MEN1KMT2A | |
| SCHEMBL1971268 | 0.91 | TACR1 (0.48) | MC4RSMN1; SMN2GPR119MEN1KMT2A | |
| SCHEMBL4153158 | 0.91 | TACR1 (0.48) | MC4RSMN1; SMN2GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | MC4R 4/4885SMN1; SMN2 1799/4885GPR119 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.